cryptocurrency play money Top Featured snippets

Pfizer announced an increase in its quarterly dividend, and American pharmaceutical giant Pfizer said on Thursday that it would increase its quarterly dividend by 2.4%, from 42 cents to 43 cents per share. The new dividend is equivalent to $1.72 per year, which means that the annual yield is about 6.8%. Albert Bourla, CEO of Pfizer, said that the dividend increase highlighted the company's strong financial performance, execution and commitment to return capital to shareholders.Ministry of National Defense: Fujian Ship will gradually launch the follow-up test project. On the morning of December 13th, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, released a message on the recent military-related issues. Reporter: According to the announcement of Shanghai Maritime Safety Administration, in early December, traffic control was implemented for the import of a large ship in the deep water channel of the Yangtze River estuary. Some analysts believe that China Navy Fujian Ship may have completed its fifth sea trial and returned to its home port. Can you confirm it? Wu Qian: It is a normal arrangement for Fujian Ship to carry out relevant tests during the construction process. In the next step, follow-up test projects will be gradually launched according to the progress of aircraft carrier construction. (issued by the Ministry of National Defense)Guotai Junan: The liquor sector is determined to be ahead of growth, paying attention to the trend of price approval and the orientation of head liquor enterprises. Guotai Junan said that the liquor reporting end began to enter a downward period in 2024Q2, and the bottom shock is expected in 2025H1. Sales are slowing down, inventory is passively rising, and the approval price is expected to be relatively weak. The Spring Festival in 2025 will experience a stress test period. In terms of price, real estate liquor > high-end > secondary high-end. After this round of adjustment, real estate liquor is expected to recover first, followed by high-end liquor, and the secondary high-end liquor is expected to recover for a long period.

Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.Media Office in the Gaza Strip: The Israeli army bombed the Nuseilet refugee camp, killing 33 people. According to Palestinian media, from the evening of 12th to the early morning of 13th local time, the Israeli army attacked the central and southern parts of the Gaza Strip, causing a lot of casualties. According to the Gaza Media Office, 33 people were killed and 84 others were missing or injured in the Israeli bombing of Nuseilet refugee camp in central Gaza on the evening of 12th. The Palestinian newspaper Al-Quds reported that Israeli troops bombed a tent for displaced people in Khan Younis, a city in southern Gaza, early on the 13th, killing two people and injuring many others.Yuejiang: It is planned to sell about 40 million H shares globally through the IPO of Hong Kong stocks. It is expected to be listed on the Hong Kong Stock Exchange on December 23, and Yuejiang announced on the Hong Kong Stock Exchange on December 13 that the company plans to sell about 40 million H shares globally, with Hong Kong public offering accounting for 5% and international offering accounting for 95%. The offer price will not be higher than HK$ 20.80 per offering share, and it is currently expected to be not lower than HK$ 18.80 per offering share, with 200 shares per lot. It is expected that the shares will start trading on the Stock Exchange at 9: 00 am on Monday, December 23, 2024, Hong Kong time.

CITIC Securities: The short-term copper price rebound has a foundation, and it pays attention to the allocation opportunities of the copper plate. CITIC Securities Research Report said that the recent TC negotiation results of copper concentrates, frequent domestic policy warm winds, and the off-season destocking of domestic stocks have been resonantly catalyzed, superimposed with the fall of the US dollar. We believe that the short-term copper price rebound has a foundation and the medium-term fundamental expectations are more solid. We predict that the copper price in the next quarter will run in the range of 9000-10000 USD/ton, which has strong upward elasticity in the short term. It is suggested to pay attention to the allocation opportunities of copper plate. It is suggested to comprehensively select stocks from the dimensions of segment valuation rationality, output growth next year and copper price elasticity.A spokesman for UnitedHealth Group said that the mother of Mangione, a suspect accused of shooting a company executive, also had no insurance for UnitedHealth.Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.